ABOUT ME
Hi! I'm Angammai Vijay Arumugam, a high school researcher, dedicated to advancing oncology and personalized medicine, through molecular immunology. My passion for cancer research stems from a fascination with how the immune system can be engineered to recognize and combat disease.
I founded Immune Insights as an independent translational platform and digital repository designed to bridge the gap between complex laboratory diagnostics and public health literacy. By focusing on the structural mechanics of the tumor microenvironment, CAR-T cell engineering, and spatial transcriptomics, my mission is to translate cutting-edge cancer research by transforming complex scientific concepts into accessible resources that empower students and lifelong learners to engage with advances in oncology and immunotherapy.
WHAT IS OFFERED
This platform features a range of educational tools and resources designed to enhance your understanding of immunology and cancer biology. Click below to learn more about our offerings.
01
Informative Articles
Discover a wide range of articles that explore the science behind immunity, cancer biology, and the innovations shaping modern medicine.
03
Educational Resources
Access a growing collection of educational materials, including infographics, slideshows, articles, and research papers that enhance learning.
02
Blog Posts
Read about topics such as cancer immunology, transcriptomics, and computational biology through thoughtfully curated easy-to-understand posts.
04
Insights
Stay updated with newsletters on concise summaries of the latest research findings, making complex studies easier to digest.
RESEARCH SPOTLIGHT
Novel bispecific TanCAR T-cell design dually targets MUC16 and LYPD3
to enhance efficacy against NSCLC with reduced CRS
Publication Details:
Author: Angammai Vijay Arumugam
Journal: National High School Journal of Science (NHSJS)
Topic: CAR T-cell Therapy & Translational Oncology
Status: Peer-Reviewed & Published
Summary:
This research paper proposes a novel dual-target tandem CAR (TanCAR) T-cell therapy for Non-Small Cell Lung Cancer (NSCLC). By dually targeting overexpressed MUC16 and LYPD3, the design prevents tumor antigen escape, while computational modeling shows that CRS toxicity is primarily driven by signaling domain strength (~44%) and antigen density (~39%) rather than receptor structure.
